InCrowd Essentials
InCrowd, Inc., member of the Apollo Intelligence family of companies
Contact Person:
Chris Mamrosh, Vice President, Research Methodology and Strategy
chris.mamrosh@incrowdnow.com
InCrowd, a pioneer of real-time, automated insights for the life sciences industry, released an agile, tech-enabled complement to the traditional tracking study. InCrowd Essentials delivers ongoing, real-time access to the market-performance metrics brand teams require through a platform that’s designed to integrate timely, event-driven research when the need arises. Further extending InCrowd’s tracking solutions as a syndicated offering, Essentials provides a leaner, fixed-price alternative to InCrowd’s award-winning MicroTracker product.
Essentials puts brand health front and center as it frees brand managers to quickly respond to problems—as well as seize opportunities—related to HCP product awareness, perceptions, prescribing, and promotional activities, among other critical metrics. Ultimately, Essentials equips life sciences brands to stay ahead of the competition and keep up with dynamic market conditions.
Essentials’ research applies a large sample size, sourced from InCrowd’s mobile-first platform and vast global panel of over two million HCPs, with real-time dashboard access, monthly fielding, and quarterly PowerPoint reports. With Essentials, brand managers can gauge product awareness in crowded markets with numerous therapeutic options, track product receptivity and adoption among HCPs, identify competitive inroads and perception changes, monitor post-launch status, and measure patient requests for specific products. Further, because it is a syndicated product, Essentials does not trigger adverse event (AE) reporting or necessitate legal review, reducing client burden.
With InCrowd’s agile, mobile-first, compliant platform, Essentials users benefit from an online dashboard showing aggregated data, updated daily. Essentials syndicated research on the respiratory syncytial virus (RSV) market is available today and is priced on a flat, quarterly rate. Essentials’ research for NSCLC, prostate cancer, and other therapeutic markets will be published in coming months.
